Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3 and 2 bp deletion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SETD2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KMT3A also known as HYPB (Huntington's disease gene-related protein B) or HIF-1 is a histone methyltransferase enzyme that mechanically transfers methyl groups to histone H3 at lysine 4 and lysine 36. This activity important for chromatin modification influences transcriptional regulation. The molecular mass of KMT3A is approximately 130 kDa. This enzyme is expressed in various tissues such as the brain heart and skeletal muscle highlighting its extensive physiological role.
Biological function summary
KMT3A modifies chromatin structure to regulate gene expression. Its histone methylation function plays a critical role in the modulation of transcriptional activity ensuring that genes are turned on or off when necessary for cellular function. Additionally KMT3A forms part of complex protein networks that mediate gene expression changes in response to cellular signals. The precise regulation of this activity is vital for maintaining normal cellular function and responding to environmental cues.
Pathways
KMT3A engages in significant pathways such as the transcriptional regulation and epigenetic modification pathways. It interacts with various proteins including CoREST and LSD1 within these pathways to modulate gene expression and influence cellular differentiation. Through these interactions KMT3A ensures the correct genetic programs are executed aligning with developmental and homeostatic requirements.
KMT3A has been implicated in neurological conditions such as Huntington's disease. The abnormal regulation or mutation of this target can disrupt its activity and lead to improper chromatin modification which results in altered gene expression and contributes to disease progression. Furthermore KMT3A's interaction with the HIF-1α pathway also links it to cancer as dysregulation can aid in tumor growth and progression by affecting gene expression patterns associated with cell proliferation and survival.
